A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers

"This study will be conducted in approximately 104 healthy subjects in up to 13 sequential dose cohorts. Thirteen cohorts will consist of up to 8 subjects, including 2 subjects receiving placebo and 6 subjects receiving iN1011-N17.~Each subsequent cohort will continue to be randomized and dosed until maximum exposure is attained or a stopping criterion has been reached."

Matching Placebo for each formulations